Clinical Trial Detail

NCT ID NCT04172597
Title A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Advanced Solid Tumor

breast cancer

colorectal cancer

malignant glioma

Therapies

Poziotinib

Age Groups: adult senior

Additional content available in CKB BOOST